RCM
RA Capital Management Portfolio holdings
AUM
$9.76B
1-Year Est. Return
103.63%
This Fund
S&P 500
1 Year Est. Return
+103.63%
AUM
$9.76B
AUM Growth
+$1.65B
(+20%)
Holding
88
Top Buys
| 1 | +$114M | |
| 2 | +$105M | |
| 3 | +$72M | |
| 4 |
Praxis Precision Medicines
PRAX
|
+$69.6M |
| 5 |
EVMN
Evommune Inc
EVMN
|
+$65M |
Top Sells
| 1 | +$292M | |
| 2 | +$141M | |
| 3 | +$55.5M | |
| 4 |
BLTE
Belite Bio
BLTE
|
+$52.4M |
| 5 |
Dianthus Therapeutics
DNTH
|
+$48.7M |
Sector Composition
| 1 | Healthcare | 99.82% |
| 2 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Exact Sciences
EXAS
$19.7B
| – | – |
-54,939
|
|
||
77
Glaukos
GKOS
$6.99B
| – | – |
-54,180
|
|
||
78
Structure Therapeutics
GPCR
$4.45B
| – | – |
-1,517,418
|
|
||
79
InflaRx
IFRX
$62.3M
| – | – |
-1,973,233
|
|
||
80
Larimar Therapeutics
LRMR
$441M
| – | – |
-6,045,351
|
|
||
81
Prime Medicine
PRME
$834M
| – | – |
-3,000,000
|
|
||
82
uniQure
QURE
$974M
| – | – |
-200,000
|
|
||
83
Arcus Biosciences
RCUS
$2.52B
| – | – |
-1,136,364
|
|
||
84
Scholar Rock
SRRK
$4.52B
| – | – |
-1,166,788
|
|
||
85
Surrozen
SRZN
$238M
| – | – |
-602,626
|
|
||
86
Tango Therapeutics
TNGX
$1.5B
| – | – |
-2,000,000
|
|
||
87
Travere Therapeutics
TVTX
$2.67B
| – | – |
-1,150,000
|
|
||
|
MTSR
88
DELISTED
Metsera Inc
MTSR
| – | – |
-675,525
|
|